Patients with multiple sclerosis (MS) have a generally increased risk of cardiovascular disease, and some evidence is emerging that disease-modifying treatments may alter this risk. Thomas Frisell, PhD, coordinator of the Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, discusses whether newer treatments for MS, such as ozanimod, may present an improved cardiac safety profile for patients with MS versus older treatments, such as fingolimod.
Patients with multiple sclerosis (MS) have a generally increased risk of cardiovascular disease, and some evidence is emerging that disease-modifying treatments may alter this risk. Thomas Frisell, PhD, coordinator of the Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, discusses whether newer treatments for MS, such as ozanimod, may present an improved cardiac safety profile for patients with MS versus older treatments, such as fingolimod.
Transcript
Do newer drugs like ozanimod present an improved cardiac safety profile for patients with MS?
So that has been argued, because that’s a drug that works like fingolimod, but is more specific, or selective, so it should have less of that transient heartrate effect. And that sounds good, right?
Well, in our data, we didn’t see an increased risk of cardiovascular disease in fingolimod either, so I’m not sure. Our data wasn’t perhaps big enough, and we didn’t have enough follow-up to really rule out increased risk on fingolimod. So it’s too early to say whether the new therapies will actually be beneficial compared to fingolimod, I would say.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More